Chok Kenneth S H, Cheung Tan To, Chan Albert C Y, Dai Wing Chiu, Chan See Ching, Lo Chung Mau
Department of Surgery, Queen Mary Hospital, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
World J Surg. 2016 Feb;40(2):412-8. doi: 10.1007/s00268-015-3239-6.
De novo hepatocellular carcinoma (HCC) complicated by pyogenic liver abscess is rare, and the standard of care for this disease has yet been defined. This study assesses whether liver resection can be recommended as its standard treatment.
This retrospective study reviewed the prospectively collected data of the 1725 patients who underwent primary liver resection for HCC at our hospital during the period from December 1989 to December 2012. Outcomes were compared between patients with and without liver abscess.
Twenty-two (1.28 %) patients had HCC and liver abscess. Fourteen of them received preoperative drainage. Patients with and without abscess had similar tumor characteristics, but patients with abscess had more operative blood loss (2.2 vs. 0.8 L; p < 0.0001) and more of them needed blood transfusion (63.6 vs. 23.1 %; p < 0.0001). They also had a longer hospital stay (38.5 vs. 10 days; p < 0.0001), a higher hospital mortality (40.9 vs. 2.8 %; p < 0.001), a higher postoperative complication rate (100 vs. 25.9 %; p < 0.0001), and poorer 1, 3, and 5-years disease-free survival rates (p = 0.023).
The post-resection mortality of the patients with de novo HCC complicated by pyogenic liver abscess was so high that liver resection is not recommended as the standard treatment. More research is needed to determine the best therapy for this rare disease.
新发肝细胞癌(HCC)合并肝脓肿罕见,且该病的治疗标准尚未明确。本研究评估肝切除术是否可作为其标准治疗方法。
本回顾性研究回顾了1989年12月至2012年12月期间在我院接受原发性肝癌肝切除术的1725例患者的前瞻性收集数据。比较了有肝脓肿和无肝脓肿患者的结局。
22例(1.28%)患者患有HCC和肝脓肿。其中14例接受了术前引流。有脓肿和无脓肿患者的肿瘤特征相似,但有脓肿患者术中失血量更多(2.2L对0.8L;p<0.0001),且更多患者需要输血(63.6%对23.1%;p<0.0001)。他们的住院时间也更长(38.5天对10天;p<0.0001),医院死亡率更高(40.9%对2.8%;p<0.001),术后并发症发生率更高(100%对25.9%;p<0.0001),1年、3年和5年无病生存率更差(p=0.023)。
新发HCC合并肝脓肿患者肝切除术后死亡率很高,因此不建议将肝切除术作为标准治疗方法。需要更多研究来确定这种罕见疾病的最佳治疗方法。